Multi-disciplinary team (MDT) perspectives for early, optimised treatment of mCRPC

Sponsored by ASTELLAS PHARMA EUROPE LTD.

Saturday 17 March
18:00 - 19:30

Location: Green Area, Room 1 (Level 0)
Chair: A.S. Bjartell, Malmö (SE)

Aims and objectives of this session
• Overview: To help clinicians understand the advantages of the MDT approach to the treatment of mCRPC
• To update clinicians on the importance of early treatment of mCRPC
• To demonstrate both a urologist’s and an oncologist’s experience of how the MDT supports strong working relationships

18:00 - 18:05
Welcome and introduction
A.S. Bjartell, Malmö (SE)

18:05 - 18:30
Exploring treatment options for patients progressing on ADT
S. Bracarda, Arezzo (IT)

18:30 - 18:50
Clinical decision making within an MDT: A urologist’s perspective
A.S. Merseburger, Lübeck (DE)

18:50 - 19:15
Discussing a mCRPC case with relevance to the MDT setting: An oncologist’s perspective
P. Hervonen, Helsinki (FI)

19:15 - 19:25
Panel discussion & audience questions
Panel: A.S. Bjartell, Malmö (SE)
S. Bracarda, Arezzo (IT)
A.S. Merseburger, Lübeck (DE)
P. Hervonen, Tampere (FI)

19:25 - 19:30
Summary and close
A.S. Bjartell, Malmö (SE)